Skip to main content

Advertisement

SpringerLink
Log in

Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Dipeptidyl peptidase 4 (DPP-4) is an enzyme that is produced by endothelial cells in different districts and circulates in plasma. Patients with type 2 diabetes show a reduction in active Glucagon-Like Peptide-1 (GLP-1) that could be due to impairment of secretion or its degradation or both. GLP-1 is rapidly inactivated in vivo, mainly by the DPP-4. Some authors suggest that Metformin has no direct inhibitory effect on DPP-4 activity and that Metformin and the other biguanides enhance GLP-1 secretion; others suggest a possible role of Metformin in the inhibition of the DPP-4 activity. In order to better elucidate the role of insulin sensitizers on the modulation of GLP-1 circulating levels, DPP-4 activity and mRNA expression were measured in cultured human aortic endothelial cells (HAEC) and human microvascular dermal endothelial cells (HMVEC) exposed to high glucose, Metformin and Rosiglitazone. Present data show that hyperglycemia is capable of increasing in a significant manner the DPP-4 activity only in microvascular endothelial cells. Rosiglitazone is able to modulate in a negative manner the expression of DPP-4 but not its activity in macrovascular endothelial cells, while at 24 h of exposure it is able to increase significantly DPP-4 activity but not its expression in microvascular endothelial cells. Metformin at 48 h only in microvascular endothelial cells is able to reduce in a significant manner (p = 0.01) the activity of DPP-4 but not its expression. The modulation of DPP-4 is site specific.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Holst JJ, Deacon CF (1998) Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663–1670

    Article  PubMed  CAS  Google Scholar 

  2. Dubový P, Kukletová MA (1992) Histochemical study by light and electron microscopy of the distribution of dipeptidyl peptidase-IV activity in the human dental pulp. Arch Oral Biol 37(1):1–6

    Article  PubMed  Google Scholar 

  3. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1-(7–36) amide, peptide histidine methionine, and is responsible for their degradation in human serum. Eur J Biochem 214:829–835

    Article  PubMed  CAS  Google Scholar 

  4. Augustyns K, Bal G, Thonus G, Belyaev A, Zhang XM, Bollaert W, Lambeir AM, Durinx C, Goossens F, Haemers A (1998) The unique properties of dipeptidyl-peptidase IV (DPP IV/CD 26) and the therapeutic potential of DPP-IV inhibitors. Curr Med Chem 6:311–327

    Google Scholar 

  5. Meneilly GS, Demuth HU, McIntosh CH, Pederson RA (2000) Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 17:346–350

    Article  PubMed  CAS  Google Scholar 

  6. Visboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentration of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients. Diabetes 50:609–613

    Article  Google Scholar 

  7. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, Cremasco F, Ognibene A, Rotella CM (2005) Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 48(6):1168–1172

    Article  PubMed  CAS  Google Scholar 

  8. Pala L, Mannucci E, Pezzatini A, Ciani S, Sardi J, Raimondi L, Ognibene A, Cappadona A, Vannelli BG, Rotella CM (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310:28–31

    Article  PubMed  CAS  Google Scholar 

  9. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Fanelli A, Messeri G, Rotella CM (2000) Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med 17(10):713

    Article  PubMed  CAS  Google Scholar 

  10. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G, Rotella CM (2001) Effects of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 24:489–494

    Article  PubMed  CAS  Google Scholar 

  11. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O’Harte FP, Flatt PR, Bell PM (2005) Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 22(5):654–657

    Article  PubMed  CAS  Google Scholar 

  12. Green BD, Irwin N, Duffy NA, Gault VA, O’harte FP, Flatt PR (2006) Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 547(1-3):192–199

    Article  PubMed  CAS  Google Scholar 

  13. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I (2002) Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 298(5):779–784

    Article  PubMed  CAS  Google Scholar 

  14. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU (2002) Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 291(5):1302–1308

    Article  PubMed  CAS  Google Scholar 

  15. Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O’Harte FP, Flatt PR (2007) Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol 568(1-3):278–286

    Article  PubMed  CAS  Google Scholar 

  16. Rotella CM, Giannini S, Galli G, Cresci B, Tanini A (1996) Role of endothelial cells in the pathogenesis of diabetic microangiopathy DNM 9:273–289

    Google Scholar 

  17. Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R, Mazzanti B, Dal Pozzo S, Mannucci E, Peri A, Serio M (2007) Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 30(9):RC26–RC30

    PubMed  CAS  Google Scholar 

  18. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real time quantitative PCR and the 2 − ΔΔCt. Methods 25:402–408

    Article  PubMed  CAS  Google Scholar 

  19. Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I (2001) Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 39:155–158

    Article  PubMed  CAS  Google Scholar 

  20. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I, Cremasco F, Messeri G, Rotella CM (2004) Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 17(6):336–342

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from the Ministry of Scientific Research (PRIN and 60% founds MIUR).

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Section of Endocrinology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy

    Laura Pala, Anna Pezzatini, Ilaria Dicembrini, Silvia Ciani, Barbara Cresci & Carlo Maria Rotella

  2. AOUC Careggi, Florence, Italy

    Laura Pala, Barbara Cresci & Edoardo Mannucci

  3. Section of Clinic Biochemistry, Department of Clinical Physiopathology, University of Florence, Florence, Italy

    Stefania Gelmini

  4. Department of Anatomy, University of Florence, Florence, Italy

    Barbara Gabriella Vannelli

Authors
  1. Laura Pala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Pezzatini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilaria Dicembrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia Ciani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefania Gelmini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barbara Gabriella Vannelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Barbara Cresci
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Edoardo Mannucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carlo Maria Rotella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Maria Rotella.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pala, L., Pezzatini, A., Dicembrini, I. et al. Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetol 49 (Suppl 1), 59–63 (2012). https://doi.org/10.1007/s00592-010-0195-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-010-0195-3

Keywords

Search

Navigation